No announcement yet.

Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

  • Filter
  • Time
  • Show
Clear All
new posts

  • Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

    Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work

    David S. Fedson

    Influenza and Other Respiratory Viruses (journal)

    Published Online: 12 Jun 2009
    Correspondence to David S. Fedson, 57, chemin du Lavoir, 01630 Sergy Haut, France.
    Copyright © 2009 Blackwell Publishing Ltd

    Host response • influenza • pandemic • peroxisome proliferator activator receptor agonists • statins

    Please cite this paper as: Fedson DS (2009) Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750-2659.2009.00090.x.

    Despite the best efforts of influenza scientists, companies and health officials to prepare for the next pandemic, most of the world's people will not have access to affordable supplies of vaccines and antiviral agents. They will have to rely on 19th century public health 'technologies' to see them through. In the 21st century, science ought to be able to provide something better. Influenza scientists study the molecular characteristics of influenza viruses and their signaling effects in cell culture and animal models of infection. While these studies have been enormously informative, they have been unable to explain the system-wide effects of influenza on the host, the increased mortality of younger adults in the 1918 influenza pandemic and the much lower mortality rates in children who were more commonly infected with the 1918 virus. Experiments by non-influenza scientists have defined common cell signaling pathways for acute lung injury caused by different agents, including inactivated H5N1 influenza virus. These pathways include several molecular targets that are up-regulated in acute lung injury and down-regulated by anti-inflammatory and immunomodulatory agents, including statins, fibrates, and glitazones. These agents also help reverse the mitochondrial dysfunction that accompanies multi-organ failure, something often seen in fatal Influenza. Observational studies suggest that statins are beneficial in treating patients with pneumonia (there are no such studies for fibrates and glitazones). Other studies suggest that these agents might be able to 'roll back' the self-damaging host response of young adults to the less damaging response of children and thus save lives. Research is urgently needed to determine whether these and other agents that modify the host response might be useful in managing H5N1 influenza and the next pandemic.

    Vaccines and antiviral agents will fail to meet global needs for the next pandemic

    Avian influenza A (H5N1) presents a serious and possibly imminent pandemic threat.2–7 Vaccine companies have worked hard to develop more efficient H5N1 vaccines,8 and the promise of using antigen sparing, adjuvanted inactivated vaccines that are cross-protective is now well established.9 In a few developed countries, stockpiling pre-pandemic vaccines is being considered.10 Nonetheless, if a pandemic virus should emerge within the next few years, the world would have to depend on a limited supply of egg-based inactivated vaccines.

    Two years ago it was estimated that all of the world's influenza vaccine companies could produce in a 6-month period (i.e., approximately 9 months after the emergence of the pandemic virus) enough doses of a new pandemic vaccine to vaccinate with two doses approximately 750 million people.11,12 More recently, a report sponsored by the World Health Organization in collaboration with virtually all influenza vaccine companies estimated that 6 months after the emergence of a new pandemic virus, the companies could produce 860 million doses of vaccine.13 These numbers are similar to the number of people living in the nine countries that produce almost all of the world's seasonal influenza vaccines. During these early months, the pandemic virus will probably have already spread throughout the world.

    Currently, there is no logistical plan for distributing supplies of pandemic vaccines to the 'have not' countries that will not be able to produce them.11,12 These countries are home to approximately 88% of the world's population. In all likelihood, people in these countries will not be able to obtain meaningful supplies of pandemic vaccines or they will get them too late.

    Many health officials have placed their hopes on stockpiles of antiviral agents.11,14,15 Recently, however, resistance to the most widely stockpiled agent – oseltamivir (Tamiflu&#174– has emerged in seasonal influenza viruses, and there is concern now that similar resistance could develop in a future pandemic virus. More important, current government stockpiles of Tamiflu in 'have not' countries would be sufficient to treat approximately 1% of the people who live in these countries (DS Fedson, unpublished data). At a scientific meeting held in Singapore in early 2008, investigators reported that among people in Indonesia who had been infected with the H5N1 virus, 33/33 (100%) of those who received no antiviral treatment died.15 This observation is terrifying: if this virus develops efficient human-to-human transmissibility and very few people have access to an effective antiviral agent, we could see a global population collapse. The possibility that this could occur was shown unequivocally in an experimental study published 35 years ago.15,16

    Our current 'top down' approach to confronting a newly emergent pandemic virus is based solely on developing and producing vaccines and antiviral agents. It relies on the decisions of relatively small groups of elite influenza scientists, national and international health officials and company executives.14,15 As such, this process has been slow and difficult to manage. Despite best efforts, most of the world's people will not have timely access to effective and affordable pandemic vaccines and antiviral agents. Instead, they will have to rely on 19th century public health 'technologies' to see them through. In the 21st century, scientists ought to be able to provide something better, especially as the consequences of not doing so could be disastrous.

    This review will suggest ways in which 21st century science could be harnessed to provide new ways of confronting the next influenza pandemic. It will not cover the extraordinary developments in our understanding of the influenza virus itself, the cell signaling events that govern its replication and determine its virulence, or the intricacies of its effects on the humoral and cell-mediated immunity; all issues covered at length in recent reviews.2–7 Instead, it will draw on lessons that can be learned from the 1918 pandemic and review selectively new information on the host response to infectious and non-infectious challenges that often result in multi-organ failure and death. It will discuss recent studies of experimental influenza and the host response and suggest ways in which currently available agents might be used to manage the next global pandemic.

    Understanding the virulence of 1918 and H5N1 influenza viruses alone will not help in managing the next global pandemic

    In attempting to explain the high mortality of 1918 and H5N1 influenza, virologists have focused their attention on molecular characteristics of the virus that are associated with receptor specificity, efficient replication, virulence and transmissibility and on the molecular effects of virus replication in cell culture and experimental animals.2–7 Experimental 1918-like and H5N1 influenza virus infections are associated with elevated levels of pro-inflammatory cytokines, often called a 'cytokine storm'.2–7,17 Similar findings characterize human H5N1 influenza.18 A broad consensus has emerged that cytokine dysregulation can be controlled and clinical improvement achieved only by early administration of an effective antiviral agent.19

    The increased virulence of the 1918 and H5N1 influenza viruses compared with seasonal influenza viruses is beyond question. Yet laboratory studies have often shown a lack of correlation between levels of virus replication and survival [reviewed in Ref. (14)]. Furthermore, experience with H5N1 influenza has shown that early diagnosis is often not possible,19 and for a global pandemic adequate supplies of antiviral agents and vaccines simply will not be available.

    Bacterial pneumonia cannot account for the majority of deaths in the 1918 pandemic

    An added level of complexity has been introduced recently by the suggestion that secondary bacterial pneumonia was the primary cause of mortality in the 1918 pandemic.20 Support for this notion comes from recent experiments showing that antecedent influenza virus infection greatly increases the risk of death following subsequent pneumococcal pneumonia.21 In a recent report, Morens et al. reviewed almost 8400 bacterial cultures of specimens taken from patients who died during the 1918 pandemic.20 After considering their findings and related epidemiological evidence, they found little to implicate the influenza virus as the sole cause of mortality. Instead, they concluded 'the vast majority of influenza deaths resulted from secondary bacterial pneumonia'. This conclusion has led to recommendations for pre-pandemic stockpiling of antimicrobial agents as well as antivirals and vaccines.

    Morens et al. have written that the 'copathogenic properties of the 1918 influenza virus may have been generic and not specific to the 1918 virus or to influenza viruses in general.22 They have found support for their view in the measles epidemics that affected US Army training camps in 1917–1918. Like the influenza pandemic 1 year later, most measles deaths were associated with bacterial pneumonia. The measles outbreaks were 'the result of an unfortunate 'natural experiment' in which young men from remote rural areas, many of whom had escaped measles virus infection in childhood, were brought together in crowded barracks during the winter/spring season of measles circulation.22 This explanation may be sufficient to explain why trainees became infected, but it does not explain why they died.

    Clinicians have known since the time of Osler that not all people who die with pneumonia necessarily die because of pneumonia.23 In patients with H5N1 influenza, virtually all who have come to medical attention have received antibiotic treatment, yet the mean duration of illness before death has been 10 days,18 as it was in 1918,24 For patients with H5N1 influenza who have presented late in the course of illness, bacterial pneumonia should have been evident, yet it has rarely been mentioned. Instead, most have gone on to develop acute respiratory distress syndrome (ARDS) and multi-organ failure.

    In the studies of bacterial pneumonia in the 1918 pandemic, one important epidemiologic feature has received little attention: children had higher influenza attack rates than young adults, yet they seldom developed bacterial pneumonia and their case fatality rates were much lower (Figure 1).20,23,24 There is nothing to suggest that the experience of children with measles in 1917–1918 was any different from that of children in earlier years.22 Virulence factors inherent in the 1918 influenza virus and the cytokine dysregulation caused by infection might help explain the increased mortality of younger adults, but there is no good reason to place the burden of 'pathogenic responsibility' entirely on the virus. Doing so overlooks a more important question: why did children live?

    In attempting to understand the high mortality in the 1918 pandemic, influenza scientists have focused their attention on young adults.25 Previous exposure to 1918-like viruses in the late 19th century seems to have given older adults a degree of protection that spared them the mortality experienced by younger adults. For children, however, there has been no satisfactory explanation for why the same virus failed to cause most of them serious harm.

    Acute lung injury is associated with many conditions and it is different in children and adults

    It is worth considering the host responses of children and adults with sickle cell disease, and malaria and those who experience severe trauma. Persons with any one of these conditions are at risk of developing acute lung injury, yet the disease is mild in children whereas in adults it is more severe and there is greater risk of dying [reviewed in Ref. (23)]. In none of these conditions do bacterial infections contribute significantly to the course of illness. Likewise, children with malaria and schistosomiasis have less vigorous immune responses to their infections than do young adults.26,27 The switch from one host response to the other seems to occur at the time of puberty/menarche/adrenarche.23 The differences between the two are poorly understood and rarely studied.

    In many bacterial, viral and parasitic diseases, there is an appreciable risk of developing acute lung injury.28,29 A similar risk is seen in non-infectious disorders such as extensive trauma or severe ischemia. In each of these conditions, the cell signaling pathways that respond to pathogen-associated molecular patterns associated with infection and danger-associated molecular patterns seen in non-infectious disorders are much the same.30 The severe acute lung injury and ARDS that develop in patients with H5N1 and other severe influenza virus infections are probably due to similar mechanisms.31

    Recent studies suggest the host response determines the outcome to severe influenza virus infection

    Given the overwhelming need for alternatives to vaccination and antiviral treatment, agents that improve the host response to influenza virus infection must be considered.11,14,15,31 Although most influenza scientists doubt this approach will work, several studies suggest it might be effective.

    In a study of mice massively infected with H5N1 influenza virus (1000 LD50), treatment with zanamivir begun 48 hours after infection reduced lung virus titers but led to little improvement in survival.32 However, when two immunomodulatory agents (celecoxib and mesalazine) were added, virus titers remained much the same but survival improved significantly. Unfortunately, the investigators failed to include a group of mice that were treated with celecoxib and mesalazine alone. If they had measured survival rates and virus titers in the two groups (two immunomodulators with and without an antiviral agent), they could have determined whether the antiviral agent was necessary for improving survival.

    A commentary that accompanied this study emphasized that co-administration of the two anti-inflammatory and immunomodulatory agents along with an antiviral agent was essential.33 Improved survival was ascribed to inhibition of cyclooxygenase (COX)-2, but it is unlikely that it was due to COX-2 inhibition alone. The cell signaling pathways involved in the regulation of COX-2 expression are complex.34 In other models of acute lung injury, COX-2 inhibition actually impairs resolution of pulmonary inflammation, probably because it prevents the up-regulation of pro-resolution factors such as lipoxin A4.35 Moreover, mesalamine is not simply a COX-2 inhibitor; it is primarily a peroxisome proliferator activator receptor (PPAR)γ agonist36 (see below).

    Another report has compared survival rates of mice sequentially infected with influenza virus and S. pneumoniae who were treated with either a cell wall-active antibiotic (ampicillin) or one of two macrolides known to inhibit bacterial protein synthesis (clindamycin or azithromycin).37 Ampicillin-treated mice had lower survival rates, presumably because of increased inflammation caused by the lysis of bacterial cell walls. The better survival of macrolide-treated animals 'appeared to be mediated by decreased inflammation as manifested by lower levels of inflammatory cells and pro-inflammatory cytokines.37 However, the greater survival of macrolide-treated mice was probably due to more than inhibition of pneumococcal protein synthesis. Macrolides have well-documented anti-inflammatory and immunomodulatory effects that improve the host response to a wide variety of non-infectious as well as infectious conditions.38–41

    A masterly study by Imai et al. has defined common set of major cell signaling events in acute lung injury due to different causes.42 It is well known that in mice, intra-tracheal instillation of acid or lipopolysaccharide (LPS) reliably induces severe acute lung injury. Imai et al. showed that both of these insults activated pulmonary macrophages. This led to oxidative stress and the formation of reactive oxygen species (ROS). ROS in turn generated large amounts of oxidized phospholipids (OxPLs) derived mostly from cellular debris. OxPLs then triggered the production of pro-inflammatory cytokines [e.g., interleukin (IL)-6] via a TLR4/TRIF/TRAF6/nuclear factor (NF)-kappaB signaling cascade (Figure 2).

    What is important about this study is that the same degree of acute lung injury and the same cell signaling cascade was observed following intra-tracheal instillation of inactivated (not live) H5N1 virus.42 The same pattern was seen in human peripheral blood mononuclear cells when they were exposed to inactivated H5N1 virus. The pulmonary lesions in mice were histologically identical to those seen in fatal cases of H5N1 influenza. None of these changes was seen with inactivated H1N1 virus.

    Among the many factors contributing to pulmonary defenses, several investigators have shown that heme-oxygenase (HO)-1 directly affects the initiation of the TLR4 signaling cascade described above.43–47 HO-1 is a stress responsive enzyme that degrades heme to carbon monoxide, biliverdin and iron. The location of TLRs within cells determines their signaling effects.46 Carbon monoxide derived from endogenous HO-1 activity limits ROS-induced TLR4 signaling by inhibiting the relocalization of TLR4 from the cytoplasm to lipid rafts on macrophage cell membranes.43 This is one of several ways in which HO-1 contributes to pulmonary host defenses and improves survival in a wide range of pathologic disorders.47

    The host response to acute lung injury due to any cause is far too complex to be captured in a single study.48,49 The same can be said about the host response in sepsis.50–53 Early and late (e.g. high molecular group box 1 (HMGB1)) mediators of inflammation, the balance between inflammatory and anti-inflammatory (e.g., lipoxin A4) factors, the contributions of innate and adaptive immunity (especially late immunosuppression50,53) (see below), disorders of the complement and coagulation systems (and their interactions), autonomic system involvement (cholinergic anti-inflammatory pathway), endocrine and metabolic dysfunction and disturbances in energy homeostasis all affect outcome in these conditions. Maintaining or restoring a balanced host response seems to be the key to recovery.

    Little is known about the molecular events that characterize the overall response of influenza patients who progress to multi-organ failure and death. Nonetheless, no virus replication occurred in the study of Imai et al.,42 so under these experimental conditions, antiviral treatment would not have affected the outcome.* These findings call into question the claim that antiviral agents are essential if treatment of H5N1 or any other severe influenza virus infection is to be effective.19 They also suggest that agents capable of interrupting one or more of the steps in the cell signaling cascade demonstrated by Imai et al. might reduce the severity of the acute lung injury seen in H5N1 and pandemic influenza, and in doing so prevent or reverse multi-organ failure and improve survival.

    Anti-inflammatory and immunomodulatory agents might be effective for treatment and prophylaxis of H5N1 and pandemic influenza

    Several lines of experimental and clinical evidence suggest that three classes of drugs – statins, PPARα agonists (fibrates), and PPARγ agonists (glitazones) might individually or in combination prevent H5N1-associated acute lung injury [reviewed in Refs (11,14,15,31)]. Each of these groups of agents (as well as several others) has been shown to inhibit the cell signaling pathways set in motion by inactivated H5N1 virus (Table 1; DS Fedson, unpublished data).42

    Statins [hydroxymethyl glutaryl - coenzyme A (HMG- CoA) reductase inhibitors] are taken every day by millions of patients with cardiovascular diseases to lower their low density lipoprotein (LDL) cholesterol levels. These agents also have anti-inflammatory (pleiotropic) effects,54 and investigators are studying their use in treating patients with sepsis55 and pneumonia. Several retrospective studies have suggested that prescriptions for statins are associated with an approximately 50% reduction in pneumonia hospitalizations and deaths [reviewed in Refs (14,15)]. A preliminary report of a randomized controlled trial of statin treatment in 67 ICU pneumonia patients showed that hospital mortality was reduced by 51%.56 Thus far, no reports have been published showing beneficial effects of statins in cell culture or animal influenza virus infections, although lack of benefit has been mentioned in one report.5

    Investigators often observe a lack of correlation between the results of treatments in experimental animals and in humans.49,57 The evidence for statin benefit in humans with sepsis and pneumonia justifies further studies, including randomized controlled trials. These studies must pay close attention to the pharmacokinetics of each agent; early evidence indicates that acute blood levels of atorvastatin might be much higher in patients with severe acute illness than they are in normal subjects.58 If statins prove to be effective against pneumonia, they might be similarly effective against H5N1 and pandemic influenza.

    Many investigators believe that fibrates – PPARα agonists that lower cholesterol levels – and glitazones – PPARγ agonists used to increase insulin sensitivity in diabetic patients – could also be used to treat acute lung injury.14,15,59 Like statins, these agents have anti-inflammatory and immunomodulatory activities.59,60 Moreover, there is considerable molecular cross-talk between statins, fibrates, and glitazones, and the pleiotropic effects of statins are achieved because of their interactions with PPARs.61,62 In experimental studies, the cell signaling effects of statins and PPAR agonists (both α and γ) can be additive.63,64 Likewise, in patients with cardiovascular diseases, the effects of therapy on biomarkers of disease are greater with combination than with single agent treatment. Given many years of use in clinical practice, the safety profile for each group of agents is well established.14

    An important study published in 2007 showed that in H2N2 influenza virus-infected mice, treatment with a common PPARα agonist (gemfibrozil) reduced mortality by 54%.65 Some have criticized this study because pulmonary virus titers were not measured. Nonetheless, it was structured like a randomized controlled trial of an acute treatment; gemfibrozil was started 4 days following infection when mice were beginning to show signs of clinical illness. Moreover, the investigators used an unambiguous end-point (death) and like a clinical trial they chose a sample size (96) that gave them statistically significant results.

    More recently, Aldridge et al. studied the effects of treatment with pioglitazone (a PPARγ agonist) in influenza-infected mice.66 They found that a subset of dendritic cells (DCs) known as tumor necrosis factor (TNF)α/inducible nitric oxide synthase DCs (TipDCs) accumulated with high frequency in the lungs of mice infected with highly pathogenic PR8 virus. TipDCs are known to recruit CCR2-positive mononuclear cells from the bone marrow and traffic them to sites of pulmonary infection. CCR2-deficient mice are generally more susceptible to non-viral infections, but CCR2-positive monocyte-derived cells have been shown to be a major cause of the immunopathology of influenza.67 Aldridge et al. speculated that pioglitazone suppression of CCL2 (the pro-inflammatory ligand for CCR2) would reduce the number of CCR2-positive mononuclear cells and increase protection. The results showed that with 3 days of pre-treatment, mortality fell from 92% to 50%. However, they also found that TipDCs increased the frequency of virus-specific CD8+ T-cells in the later stages of infection. As CD8+ T-cells are critical for influenza virus clearance, TipDCs appeared to induce a protective response. Yet, protection was not reflected in pulmonary virus titers; they were the same in control and pioglitazone-treated animals. Thus, although pioglitazone was able to 'tip the balance' in favor of protection,68 it must have done so through mechanisms that were independent of its effects on virus replication and clearance.

    The study by Aldridge et al. was not designed to test whether pioglitazone could be used to treat an already established infection, unlike the gemfibrozil study discussed above.65 As such, the findings are similar to those obtained in the observational studies that have shown that patients already taking statins have reduced rates of pneumonia hospitalization and death (i.e., both act as prophylactic agents).14,15 Interestingly, if reducing the number of CCR2-positive mononuclear cells has any role to play in recovery from influenza, statins are known to suppress CCR2 gene expression and monocyte recruitment,69,70 and might have effects similar to those seen with pioglitazone.

    Several other agents with anti-inflammatory and immunomodulatory or even antiviral activities should be considered for treatment and prophylaxis of H5N1 and pandemic influenza [reviewed in Ref. (14)]. For example, in cell culture chloroquine, a classic anti-malaria drug, impairs lysosomal acidification, preventing the release into the cytoplasm of viral nucleic acid from H3N2 and H1N1 but not H5N1 influenza viruses [discussed in Ref. (14)]. The many effects of catechins (found in green tea) and curcumin (turmeric in curry) on inflammation and the host response suggest that they too might be beneficial against influenza.

    A potentially important but overlooked compound is resveratrol, a commonly available polyphenol found naturally in dark grapes and red wine. In a study of influenza PR8-infected mice, resveratrol treatment inhibited virus replication and reduced mortality by half.71 Resveratrol has statin-like effects on HMG-CoA,72 activates PPARα73 and PPARγ,74 and synergizes with statins in protecting against experimental myocardial infarction.75 The effects of resveratrol on ROS, TLR4, NF-kappaB, pro-inflammatory cytokines (e.g., TNFα, IL-6), and HO-1 are the same as those of statins, fibrates, and glitazones (see Table 1).76–78 In experimental Serratia marcescens pneumonia in rats, resveratrol has been shown to down-regulate NF-kappaB, TNFα, IL-6, and IL-1β, increase macrophage infiltration, decrease neutrophil infiltration, reduce the bacterial burden in the lung and improve survival.78

    The report on the efficacy of resveratrol treatment of influenza in mice was published in 2005 by investigators who work outside the influenza scientific community.71 Remarkably, this important study has gone unnoticed by mainstream influenza scientists.

    Other aspects of the host response might be affected by statins, fibrates and glitazones

    The pathologic effects of influenza virus infection are mediated though several pathways, of which three might be targets of treatments that modify the host response.


    Much attention has been given recently to the role of inflammasomes in the host response to influenza virus infection. Inflammasomes are multi-protein complexes that are responsible for the activation of caspase-1 that, in turn, generates two pro-inflammatory cytokines – IL-1β and IL-18.79 Among the three major groups of pattern recognition receptors – TLRs, retinoic acid inducible gene-I-like receptors and the Nod-like receptors (NLRs) – inflammasomes are part of the NLR family of receptors, and they participate in the innate and adaptive immune response. For influenza virus infection, the NLRP3 inflammasome seems to be important.

    Two recent studies by Allen et al.80 and Thomas et al.81 have examined the responses of PR8-infected knockout mice deficient in caspase-1 or NLRP3. Compared with wild-type mice, mice with either deficiency had lower survival rates and reduced numbers of mononuclear cells and neutrophils in their lungs. Although the histological findings in the lungs of knockout mice in the two studies differed, it was clear from both studies that NLRP3 was protective. Both macrophages and epithelial cells were involved in early NLRP3 signaling, but compared with wild-type mice, much lower levels of IL-1β and IL-18 were found in the bronchoalveolar fluid of mice deficient in caspase-1 and NLRP3. Neither deficiency, however, had an appreciable effect on the adaptive immune response.80–82

    These studies demonstrate the importance of NLRP3 signaling pathways in mounting a controlled inflammatory response to influenza virus infection.83 Moreover, the study by Thomas et al.81 showed that the NLRP3 inflammasome response could be triggered by intra-peritoneal administration of influenza viral RNA alone. In other words, virus replication was not required to trigger a protective inflammatory response.

    These findings might be relevant to those obtained in a study of patients with sepsis. Reductions in caspase-1 signaling were found in those with septic shock compared with other critically ill patients who were not in shock.84 Down regulation of caspase-1 signaling suggested that mononuclear cell dysfunction appeared in patients with more severe illness. Importantly, an experimental study of mitogen-activated mononuclear cells has shown that statins activate caspase-1 and increase IL-18 secretion, thus reversing mononuclear cell dysfunction.85 Whether statins and other agents (e.g., fibrates and glitazones) would produce the same response in influenza virus infections remains to be determined.

    Apoptosis and autophagy

    Almost all patients with seasonal and pandemic influenza survive, but for those who die there is little understanding of the factors responsible for their deaths. The emergence of H5N1 influenza and its high case fatality rate has focused attention on the 'cytokine storm' that accompanies infection.2–7 This is surely not the only factor and perhaps not even the main factor responsible. A better understanding of the probable pathogenesis of fatal influenza can gained from studies of fatal sepsis.50,53. Among sepsis patients who die, few die within the first few days. Most develop a sustained 'immunoparalysis' and die much later. Apoptosis (programmed cell death) is the central feature of this late stage of disease. With apoptosis, there is a profound decrease in the numbers of lymphocytes – B-cells and CD4+ T-cells, the critical effector cells of the adaptive immune response. DCs are also lost, compromising antigen presentation. Uptake of apoptotic cells by macrophages and DCs stimulates the release of anti-inflammatory cytokines (e.g., IL-10 and TGF-β) and induces immune suppression. Apoptotic cell death can follow extrinsic (caspase-8-mediated) or mitochondria-initiated (caspase-9-mediated) pathways, and both are involved in sepsis-induced lymphocyte depletion. Experimental studies show that caspase inhibition improves survival, but it has been difficult to develop caspase inhibitors suitable for clinical use.50,86

    Autophagy is a cellular pathway that is central to cell preservation and turnover.87 It involves the self-digestion of proteins and cell organelles that are part of normal homeostatic cell function, but it also involves the response to stress (e.g., starvation, infection). The molecular interactions between autophagy and apoptosis are not well understood,87,88 but 'coordinated regulation of 'self-digestion' by autophagy and 'self-killing' by apoptosis may underlie diverse aspects of … disease pathogenesis'.87

    Autophagy and apoptosis are features of influenza virus replication. That autophagy is involved is not surprising,89 as the virus must use the building blocks at hand to form new virus particles. Apoptosis also accompanies influenza virus infection. In cell cultures of human blood macrophages, the onset of apoptosis induced by H5N1 viruses is delayed compared with that for H1N1 viruses,90 suggesting that intracellular persistence of the H5N1 virus might have something to do with its pathologic effects. In other studies, H5N1 virus (but not H5N2 or H5N3 viruses) was shown to induce caspase-dependent apoptosis in porcine alveolar epithelial cells, although levels of virus replication for all three viruses were the same.91 The H5N1 NS1 protein has also been shown to cause caspase-dependent apoptosis in human lung epithelial cells.92

    In a splendid study of murine influenza, the PB1-F2 protein of the 1918 influenza virus was shown to cause severe viral and secondary pneumococcal pneumonia.93 PBI-F2 is known to have no major effect on virus replication. Instead, by localizing to the inner and outer mitochondrial membranes, it disrupts mitochondrial morphology and dissipates mitochondrial energy potential, causing apoptosis and cell death. It is thought that apoptosis of immune cells prevents efficient maturation of the adaptive immune response, and that this explains its pathologic effects. Remarkably, the effects of the 1918 PB1-F2 protein can be produced by intranasal administration of only the C-terminal portion of the protein.93

    In a limited study of two patients who died of H5N1 influenza, apoptosis was seen in alveolar epithelial cells and pulmonary leukocytes.94 Apoptotic lymphocytes were also found in the spleen but there was no evidence of virus replication, suggesting that unidentified host factors were responsible. Considered together, the findings from the studies discussed above indicate that apoptosis is not directly related to high levels of influenza virus replication. Instead, it is caused by poorly defined host factors that respond to the molecular features of the virus such as the PB1-F2 and NS-1 proteins and perhaps viral RNA81 and those of the host cells damaged by infection.

    There have been no studies that report the effects of statins, fibrates, or glitazones on autophagy or apoptosis in acute lung injury due to any cause. However, the apoptosis observed in septic cardiomyopathy is reduced with statin treatment, with a corresponding improvement in cardiac function.95 Furthermore, in a rat model of hepatic ischemia/reperfusion injury, simvastatin pre-treatment reduced the amount of apoptosis, with an associated improvement in liver function.96


    Studies of experimental and human sepsis97,98 have shown that mitochondrial dysfunction and the disruption of energy homeostasis could be responsible for much of the loss of pulmonary integrity and the multi-organ failure seen in acute lung injury. Thus, mitochondrial dysfunction could play a fundamental role in determining the outcome of H5N1 and pandemic influenza virus infection.

    Mitochondrial dysfunction is responsible for oxidant-induced acute lung injury99,100 in a process that is regulated by peroxisome proliferator activator receptorγ co-activator (PGC)-1a.101,102 In mice with experimental bacterial sepsis103 and in critically ill patients,104 restoration of mitochondrial function clearly separates those who recover from those who die. Mitochondrial biogenesis can be restored by up-regulating HO-1105 and by glitazones.106 In a model of LPS-induced mitochondrial dysfunction in murine neutrophils, inhibition of mitochondrial respiratory complex 1 with metformin led to decreased activity of NF-kappaB and lower levels of pro-inflammatory cytokines.107 In whole animal studies, LPS-exposed mice treated with metformin showed an inhibition of mitochondrial respiratory complex 1 in the lungs and a reduction in the severity of acute lung injury.107 Glitazones and fibrates have the same down regulating effect on mitochondrial respiratory complex 1 as metformin.108,109

    Mitochondrial dysfunction with diminished cardiac function is a late occurring event in the myocardial depression seen in sepsis, but these changes might actually be protective.110 By reducing energy expenditure when mitochondrial energy generation is compromised, a state analogous to hibernation is induced that maintains myocardial integrity until recovery sets in.

    Unfortunately, there is little information on the effects of statins, fibrates, and glitazones on mitochondrial functioning in acutely ill patients, and it must be remembered that the toxic effects of each group of drugs are thought to be due to their effects on mitochondria.111 Nonetheless, in a clinical trial conducted in children with severe burn injury and mitochondrial dysfunction, mitochondrial biogenesis was restored by treatment with fenofibrate.112

    Research on the host response should determine whether anti-inflammatory and immunomodulatory agents could be used to manage the next pandemic

    In focusing on the structural characteristics of influenza viruses that are associated with receptor specificity, replication efficiency, virulence and transmissibility and on factors that affect virus-induced cell signaling and cytokine dysregulation,2–7 influenza scientists have largely ignored the system-wide effects of the disease (multi-organ failure) and have left unexplored differences in system-wide molecular pathophysiology that might explain the remarkably different mortality rates in children and young adults seen in the 1918 pandemic. The well-known ability of some species (e.g., guinea pigs113) to support high levels of influenza virus replication without developing illness must reflect intrinsic host factors that differ from those of other animals that develop severe disease. The molecular consequences of influenza's effects on cardiac function and on organs other than the lung are hardly known. The pulmonary infiltrates seen in patients with H5N1 influenza that have been attributed to local cytokine dysregulation, could well be due to the influx of pro-inflammatory factors generated in the liver114 or perhaps other organs.

    The similarities in the clinical course of patients with 1918 and H5N1 influenza and that of patients with sepsis are striking. The median duration of illness from onset until death in 1918 and H5N1 influenza has been similar to that seen in sepsis.18,24 The time courses for the development of lymphocyte depletion and multi-organ failure are generally the same. Bacterial super-infection is often associated with late immunosuppression seen in patients with sepsis and in those with acute lung injury due to non-infectious conditions like severe trauma. Thus, it is reasonable to assume that many of the pneumonia deaths seen in the 1918 pandemic had a similar cause. It is also reasonable to assume that agents shown to be effective in treating one condition might also be effective in treating the other, as has already been suggested for statins in both sepsis55 and pneumonia.14,15 As noted recently by Hotchkiss et al., 'reengagement or preserving host immune function will be the next major advance in the management of patients with sepsis.53 The same could be said for the management of patients with severe and pandemic influenza.

    Surgeons have provided clues on how pandemic influenza could be managed

    Surgeons who care for patients with multiple trauma have noted that secondary acute lung injury is less common and less severe in children than it is in young adults, and that it also has a lower mortality rate.115 The cytokine profiles of children and adults with severe burns differ greatly.116 Surgeons have also shown that the inflammatory responses of peritoneal macrophages harvested from children and young adults differ. When challenged in vitro with LPS117 or IL-1β,118 macrophages from children showed a greater predominance of anti-inflammatory activity compared with those from adults.

    A model of severe acute inflammation in mice has provided a clue to how anti-inflammatory and immunomodulatory treatment might improve outcomes in severe influenza. Shin and his surgical colleagues showed that following ischemia/reperfusion injury in mice, inflammation was much more severe in 'young adults' (10–12 week old mice) than it was in 'children' (4- to 5-weeks old) (Table 2).119 The liver cells of 'children' showed up-regulation of PPARγ that was more pronounced and lasted longer that what was seen in 'young adults.' In 'children,' PPARγ activity was retained in the nucleus, whereas in 'young adults' it leaked into the cytoplasm. The liver cells of 'children' also showed greater evidence of autophagy than did those of 'young adults.' Importantly, when 'young adults' were treated with a PPARγ agonist (rosiglitazone), PPARγ activity was up-regulated in liver cells to levels similar to that seen in untreated 'children'.

    Knowledge such as this could help us prepare for the next influenza pandemic. If PPARγ agonists are able to control acute lung injury, as has been suggested,120 the results of the study by Shin et al. suggest that treatment of young adults might, in effect, 'roll back' the host response of someone who is sexually mature and a poor PPARγ responder (and who might die) to that of a sexually immature child who is a better PPARγ responder (and more likely to live). Whether treatment with fibrates or statins would have a similar effect is unknown and should be studied.

    If effective agents can be found, treatment in a pandemic might need to be given only to patients who are on the verge of developing severe, life-threatening illness and continued only until they had recovered. Since most patients infected with a pandemic influenza virus might be expected to have a balanced host response and recover uneventfully (perhaps H5N1 excepted), it would not be necessary to make treatment available for entire populations. Instead, smaller supplies could be stockpiled and reserved for treating only those individuals (perhaps only 2–10% of a population) who might truly benefit.

    Speculation such as this is based largely on observations in settings other than experimental and human influenza. These ideas might eventually be shown to be incorrect. However, they serve to illustrate the narrowness of our current knowledge of the host response to severe influenza. They also emphasize how this narrowness continues to limit our search for practical ways to manage the next pandemic.

    It should be evident that any treatment shown to be effective in modifying the host response and reducing mortality in patients with pandemic or seasonal influenza should also be useful in treating patients with sepsis and other conditions characterized by a dysregulated inflammatory response and late immunosuppression. One such treatment (rosiglitazone) has already been shown to be effective in treating experimental cerebral malaria.121

    The global relevance of research on the host response to influenza

    What is overwhelmingly important about the anti-inflammatory and immunomodulatory agents discussed here – statins, fibrates, glitazones, and several others – is that they are now being produced as inexpensive generic medications and are widely available in 'have not' countries.11,14,15,31 For example, in the US a 5-day course of treatment with a generic statin would cost $3·20 and a course of resveratrol would cost $1·80 (DS Fedson, unpublished data). In developing countries they would cost even less. They could be stockpiled and made available in each country on the first pandemic day. It is unlikely that this will ever be said for pandemic vaccines and antiviral agents.

    More research is needed to determine whether agents that modify the host response will be useful for the treatment and prophylaxis of H5N1 and pandemic influenza. A five-point research agenda was recently proposed, and an adaptation is shown in Table 3.15 The first two points address studies to be carried out by laboratory-based investigators. If these studies are focused on identifying promising candidates for patient treatment, they should not require a great deal of time or money, but they would need to be sponsored. As pointed out recently,33 studies of generic agents for pandemic treatment are of no commercial interest to pharmaceutical companies and there is no identifiable patient group to advocate they be undertaken. Thus, the studies can only be undertaken if there is strong support from governments or foundations.

    Table 3. A research agenda to establish whether anti-inflammatory and immunomodulatory agents could be used for treatment and prophylaxis of an H5N1-like influenza pandemic*

    Test promising treatment regimens in mice, ferrets, and non-human primates to identify specific agents that might be effective in managing an H5N1-like pandemic

    Later study promising treatments in cell culture and animals to define the molecular mechanisms that explain their beneficial effects against H5N1 and 1918-like viruses

    Conduct a global analysis to identify developing countries where these agents are produced and determine quantities produced, surge capacities, patterns of distribution and costs to public programmes

    Establish an international process to coordinate or manage the stockpiling of these agents and/or their distribution once a pandemic virus has emerged

    Plan to conduct randomized controlled trials of promising treatments immediately after the emergence of a new pandemic virus
    *Adapted from table 3 in Ref. (15).
    Randomized controlled trials of promising treatments will be more difficult than the laboratory studies.122 The results of sepsis trials of these agents might not be available for many years and there might not be sufficient time or opportunity to organize and conduct large-scale clinical trials for treating seasonal influenza. Thus, it will be essential to undertake detailed planning so that clinical trials can be conducted in the first few weeks of the next pandemic when large numbers of patients will be immediately available and can be easily enrolled.15

    The research agenda outlined in Table 3 is much too important to be left to influenza scientists alone. It must involve other investigators with expertise in the cellular and molecular biology of inflammation, immunity, sepsis, cardiopulmonary diseases, critical care, endocrinology and metabolism and mitochondrial function. Influenza scientists must realize that they cannot do this work by themselves; they need the help of others. Likewise, scientists in other disciplines must be persuaded that their expertise will be essential if we are to adequately prepare ourselves for the next pandemic.


    There is no guarantee that treatment with one or more anti-inflammatory and immunomodulatory agents alone will mitigate the effects of an H5N1 or pandemic influenza virus infection. Nonetheless, scientists and the health officials who support their work must choose whether to undertake the necessary laboratory and clinical research before the pandemic arrives, and perhaps discover that generic agents will not be useful, or undertake it after the pandemic has passed, only to discover that millions could have been saved. This choice can no longer be avoided.

    Most of the world's people lack realistic alternatives for confronting the next pandemic. Without the availability of treatments that will prevent multi-organ failure and death, millions are expected to die, and with an H5N1 pandemic the global death toll could reach hundreds of millions. For this reason alone, it is essential that the research outlined here be undertaken immediately.

    [See article link for Tables, images, Footnotes/References]

  • #2
    Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

    Its frightening that this paper is not getting more exposure.


    • #3
      Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

      Originally posted by St Michael View Post
      Its frightening that this paper is not getting more exposure.
      It is more frightening that the "structures" give up on early and actual isolation and containments, knowing that we will be practicaly empty handed in front of the pandemic waves.

      First the oldies are old so triage them by paliatives ...,
      then the middle aged have many underlaying conditions so let it go working until they fall ...,
      the childrens/teens are subjected by learnings, they must be "educated" so let them party ...,
      who remains?

      The fraction ...


      • #4
        Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

        I congratulate Dr. Fedson on his excellent paper and as one who has planned to provide medical care to pandemic influenza victims be they from A/(novel)H1N1 or A/H5N1 or some combination of these and seasonal flu, the information provided in this document will be put to good use. Thanks very much.

        While not in the same league as the author, I would like to take a few minutes to summarize some of the important points I got from this article. First, the world as a whole will not have access to efficacious vaccines or anti-viral medications. Second, those in the rich and poor nations alike will need to rely primarily on basic influenza treatment methods given in the home like ensuring good hydration, adequate warmth and cleanliness, and other supportive measures. These low tech treatments will suffice for the vast majority of those ill with pandemic influenza.

        Dr. Feldson stipulates that in a small percentage of patients, up to 10%, that the common sense supportive measures mentioned above will be inadequate due to severe immune system dysregulation; an event that is the probable cause of most of the deaths seen during the 1918 pandemic and with H5N1 today. {I would add that this is also the probable cause of many of those who have died in North American due to A/(novel)H1N1}

        This position is in contrast to that of several recent authors who proposed that the majority of those who died during the 1918 pandemic were the victims of post-influenza bacterial pneumonia. {I support Dr. Fedson's position in this regard. Certainly there were many people who died in 1918 from post-influenza bacterial pneumonia but not the majority in my opinion}.

        The principal point made by Dr. Fedson in this paper is that immune dysregulation caused by influenza is what results in muli-organ failure and death in the majority of patients with pandemic influenza. He follows this position with the intriguing assertion that the immune system dysfunction can be mitigated by the use of several inexpensive and widely available drugs and foods that have been shown experimentally to reduce immune system dysregulation and death in both people and animal models of infectious disease including those due to bacteria and the influenza virus.

        The drugs mentioned include statin drugs prescribed for treatment of elevated cholesterol levels (atorvastatin (Lipitor), simvastatin (Zocor), pravastatin (Pravacol), Mevacor, Crestor; the fibrate class of drugs used for treatment of elevated triglycerides including gemfibrizole and Tricor, and the glitazones and metformin that are indicated for the treatment of type II diabetes. In addition to these he mentions the experimental benefits of the use of cox II inhibitors like Celebrex indicated for treatment of pain and arthritis.

        It is of interest that he mentions turmeric and catechin, a chemical found in green tea as potentially useful immune regulators for treatment of patients with influenza. He also comments favorably on the potential benefits of an extract of dark grape peals found in juice and red wine, resveratrol on mortality in mice exposed to influenza virus. Resveratrol can be obtained from cheep red wine and grape juice but is also available commercially. I have not really investigated this product before but will do so now given Dr. Fedson's endorsement. I would say however that the commercial advocates of this product have been very aggressive in a way that has turned me away from even considering it in the past; so be careful.

        In essence, use of any of these agents during severe infections in humans or mice resulted in a 50% reduction in mortality compared to those not treated with them. What's more Dr. Fedson opines that there could be additive benefits to patients who receive combination treatment with two or more of these agents.

        Dr. Fedson makes it very clear in the article that his observations have not been proven correct in randomized clinical trials, which he calls for.

        As a clinician practicing medicine at the start of one influenza pandemic with the prospect of H5N1 in the wings, the guidance provided by Dr. Fedson is very welcome. Frankly, there is no time for randomized clinical trials to give us the answer here. What doctors like me will have to do is apply these remedies to those we think are most likely to benefit from them without the certainest of a RCT to stand behind.

        As pointed out by Dr. Fedson, a number of the drugs he mentions as of potential benefit for treatment of immune dysregulation due to influenza are inexpensive being available as generics. For instance, two of the statins and one of the fibrates can be purchased from US pharmacies for as little as $4 for a months supply, more than enough for influenza treatment. Tumeric and green tea are also relatively inexpensive.

        Grattan Woodson, MD
        The Doctor


        • #5
          Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

          Great summary Dr. Woodson, thank you!


          • #6
            Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

            My pleasure.

            The Doctor


            • #7
              Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

              ......... number of the drugs he mentions as of potential benefit for treatment of immune dysregulation due to influenza are inexpensive being available as generics. For instance, two of the statins and one of the fibrates can be purchased from US pharmacies for as little as $4 for a months supply, ...........
              $4.00? Is that "four" dollars?

              I just picked up a month's statins supply and the retail is $178.08 (Simvastatin and Trilipix{in place of Tricor}).

              Which one is $4.00? What are interactions for that one?

              "The next major advancement in the health of American people will be determined by what the individual is willing to do for himself"-- John Knowles, Former President of the Rockefeller Foundation


              • #8
                Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

                Yes $4.00 is correct.

                In fact you can buy a 90 day supply of mevacor or pravastatin (for high cholesterol) for $10 from Kroger, Wal-mart, Sam's Club or Costco.

                You can also purchase gemfibrizole (for high triglycerides) for the same price.

                Metformin (for diabetes type II) is also available for this low price.

                The Doctor


                • #9
                  Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

                  and what costs the prescription ?
                  I'm interested in expert panflu damage estimates
                  my current links: [url][/url] ILI-charts: [url][/url]


                  • #10
                    Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

                    i wonder is Red Yeast Rice (reported to contain a natural statin) would have the same effect. See here for a current article.

                    I want to insert that this product is unregulated, so the potency and actual contents may not be as expected. There also needs to be considerable study to ascertain if claims are true.

                    "The next major advancement in the health of American people will be determined by what the individual is willing to do for himself"-- John Knowles, Former President of the Rockefeller Foundation


                    • #11
                      Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

                      Originally posted by gsgs View Post
                      and what costs the prescription ?
                      No cost other than the expense of the visit to the doctor and the cost to purchase the medicine.
                      The salvage of human life ought to be placed above barter and exchange ~ Louis Harris, 1918


                      • #12
                        Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

                        Originally posted by the doctor View Post
                        In fact you can buy a 90 day supply of mevacor or pravastatin (for high cholesterol) for $10 from Kroger, Wal-mart, Sam's Club or Costco.

                        You can also purchase gemfibrizole (for high triglycerides) for the same price.
                        It may not be safe to coadminister gemfibrozil and statins:

                        Gemfibrozil, when used together with the statin family of cholesterol-reducing medications ... increases the risk of a condition called rhabdomyolysis (muscle injury) which when severe can lead to kidney damage and seven death. Rhabdomyolysis may occur as early as three weeks or several months after starting combination therapy. The benefit of combining gemfibrozil with statins does not outweigh the risk of rhabdomyolysis.
                        Supposedly the newer fibrate Tricor (fenofibrate) does not have this interaction, and many doctors are using Tricor in combination therapy with statins.


                        • #13
                          Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents


                          Science flu science update: 18 June 2009

                          Carol Campbell

                          18 June 2009 | EN

                          Cheap, widely-available generic drugs could save millions of lives in developing countries without access to antivirals

                          A leading vaccine expert has suggested looking at the host rather than the virus in attempts to tackle the swine flu influenza A(H1N1) pandemic.

                          In a paper published last week in Influenza and other Respiratory Diseases, David Fedson says that cheap, widely-available generic drugs that alter people's immune response could save millions of lives in developing countries without access to a vaccine or antivirals.

                          Fedson suggests more research should be done into using statins, fibrates and glitazones agents normally used by doctors for treating diabetes and high cholesterol to see if they could help manage an influenza pandemic.

                          He adds that while influenza researchers are aware of this hypothesis, few resources have been invested in pursuing it.

                          "If they could be shown to be effective in treating severe influenza, they could be made available to people in all countries on the first pandemic day. The studies would not be very expensive, and the important ones could probably be completed in less than six months," he told SciDev.Net.

                          WHO director-general Margaret Chan is continuing negotiations with pharmaceutical companies to make antivirals and vaccines available to the developing world. GlaxoSmithKline has already pledged 50 million doses of vaccine and Sanofi-Pasteur announced a donation of 100 million doses yesterday (17 June), while smaller companies have promised a percentage of their production.

                          But the Financial Times reported that Swiss pharmaceutical giant Novartis said it would not donate swine flu vaccine to the developing world. The newspaper said this was "a rebuff to Chan" who had hoped for "solidarity" in fighting the pandemic.

                          Daniel Vasella, Novartis chief executive, told the Financial Times: "If you want to make production sustainable, you have to create financial incentives."

                          In an editorial following Novartis' announcement, the Financial Times pointed out that 85 per cent of the burden of chronic disease falls in low- and middle-income countries suggesting that more deaths from influenza A(H1N1) would occur there.

                          The newspaper called on rich nations to stand ready "not only to pay for other people's drugs" but, if the WHO thinks it necessary, "to give up some of their own vaccine stocks".

                          The scale and impact of swine flu was outlined in a set of maps this week by the risk specialist company Maplecroft. Science Daily reported that the Influenza Pandemic Risk Index consists of three categories: risk of emergence, risk of spread and capacity to contain.

                          For many Sub-Saharan African countries the capacity to contain is "extreme" not good as is the risk of spread. Algeria, China, Egypt and South Africa are all listed as "medium" in their ability to contain the virus.


                          • #14
                            Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

                            UPI finally picked up on this:

                            Expert says generic drugs may aid pandemic

                            Still nothing from the other wire services


                            • #15
                              Re: Dr. Fedson: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents

                              Originally posted by St Michael View Post
                              It may not be safe to coadminister gemfibrozil and statins:

                              Supposedly the newer fibrate Tricor (fenofibrate) does not have this interaction, and many doctors are using Tricor in combination therapy with statins.
                              This is true but mainly only when these two classes of drugs are used for chronic treatment of mixed hyperlipidemia (high cholesterol and triglycerides) on a long-term basis.

                              What I anticipate doing is beginning them ASAP after onset of influenza and stopping them after a couple of weeks. When used short-term like this, the risk of any severe side effects is so low as to be nil.

                              Grattan Woodson, MD
                              The Doctor